USE of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone

Head and Neck

Volumn 31, Issue 1, 2009, Pages 9-20

  Chung, Yih Lin ^a,b   Lee, Ming Yuan ^a,b   Horng, Cheng Fang ^a   Jian, James Jer Ming ^a,c   Cheng, Skye Hongiun ^a,c   Tsai, Stella Y ^a,c   Hsieh, Cheng I ^a   Yen, Lawrence K ^a   Lin, Ching Yuan ^a  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle protein; Chemoradiotherapy; Human papillomavirus; Prognosis; Tonsillar cancer

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; FLUOROURACIL; PROTEIN P21; PROTEIN P53; VIRUS DNA;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTINUOUS INFUSION; DNA SEQUENCE; DNA VIRUS; ENVIRONMENTAL EXPOSURE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PUNCH BIOPSY; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STAINING; TISSUE MICROARRAY; TONSIL CARCINOMA; TREATMENT DURATION; VIRUS DETECTION; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; GENE DOSAGE; GENES, TUMOR SUPPRESSOR; HERPESVIRUS 4, HUMAN; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PLASMIDS; RADIOTHERAPY DOSAGE; TISSUE ARRAY ANALYSIS; TONSILLAR NEOPLASMS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 58149523375     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20913     Document Type: Article

References (48)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-1900.
2. Lingen M, Sturgis EM, Kies MS. Squamous cell carcinoma of the head and neck in nonsmokers: clinical and biologic characteristics and implications for management. Curr Opin Oncol 2001;13:176-182.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
4. Young LS, Murray PG. Epstein-Barr virus and oncogene-sis: from latent genes to tumours. Oncogene 2003;22: 5108-5121.
5. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human pap-illomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-1136.
6. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992;89:4442-4446.
7. Burkhart BA, Alcorta DA, Chiao C, Isaacs JS, Barrett JC. Two posttranscriptional pathways that regulate p21Cip1/Waf1/Sdi1 are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 1999;247:168-175.
8. O'Nions J, Allday MJ. Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 2003;22: 7181-7191.
9. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A 1993;90:5455-5459.
10. Okan I, Wang Y, Chen F, et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995;11:1027-1031.
11. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
12. Liauw SL, Mancuso AA, Amdur RJ, et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 2006;24:1421-1427.
13. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillo-mavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007;67: 4605-4619.
14. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Natl Cancer Inst 2008;100:261-269.
15. Hafner N, Driesch C, Gajda M, et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008;27:1610-1617.
16. de Boer MA, Jordanova ES, Kenter GG, et al. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res 2007;13:132-138.
17. Tune CE, Liavaag PG, Freeman JL, et al. Nasopharyn-geal brush biopsies and detection of nasopharyngeal cancer in a high-risk population. J Natl Cancer Inst 1999; 91:796-800.
18. Rose BR, Thompson CH, Chantrill LA, Tattersall MH, Cossart YE. Prevalence and distribution of human papil-lomavirus type-16 DNA in pelvic lymph nodes of patients with cervical cancer and in women with no history of cervical abnormality. Int J Cancer 1992;52:225-228.
19. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papilloma-virus detection by PCR. J Gen Virol 1995;76:1057-1062.
20. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hilde-sheim A, Jenison SA. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 1995;69:7743-7753.
21. Boxman IL, Berkhout RJ, Mulder LH, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997;108:712-715.
22. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-2193.
23. Peitsaro P, Johansson B, Syrjanen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 2002;40: 886-891.
24. Cerovac Z, Sarcevic B, Kralj Z, Ban J. Detection of human papillomavirus HPV type 6, 16 and 18 in head and neck squamous cell carcinomas by in situ hybridization. Neoplasma 1996;43:185-194.
25. Li W, Thompson CH, Cossart YE, et al. The expression of key cell cycle markers and presence of human papillo-mavirus in squamous cell carcinoma of the tonsil. Head Neck 2004;26:1-9.
26. CIP1/WAF1 protein accumulation in head-and-neck cancer. Int J Cancer 1997;74:383-389.
27. Esrig D, Spruck CH III, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-1397.
28. Roesch A, Becker B, Meyer S, et al. Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol 2005;8: 565-572.
29. Li W, Sanki A, Karim RZ, et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006;38:287-301.
30. Hopman AH, Kamps MA, Smedts F, Speel EJ, Herring-ton CS, Ramaekers FC. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer 2005;115:419-428.
31. Li W, Thompson CH, O'Brien CJ, et al. Human papilloma-virus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003;106: 553-558.
32. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006;24:5630-5636.
33. Weinberger PM, Yu Z, Haffty BG, et al. A. molecular classification identifies a subset of human papillomavirus - associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736-747.
34. Cheng SH, Jian JJ, Tsai SY, et al. Prognostic features and treatment outcome in locoregionally advanced naso-pharyngeal carcinoma following concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:755-762.
35. Selek U, Garden AS, Morrison WH, El-Naggar AK, Rosenthal DI, Ang KK. Radiation therapy for early-stage carcinoma of the oropharynx. Int J Radiat Oncol Biol Phys 2004;59:743-751.
36. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;8:1465-1473.
37. Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. J Clin Oncol 2006;24:5623-5625.
38. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 2005;97:1023-1025.
39. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004;96:998-1006.
40. Smeets SJ, Braakhuis BJ, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squa-mous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006;25:2558-2564.
41. Haraf DJ, Nodzenski E, Brachman D, et al. Human pap-illoma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996;2:755-762.
42. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-1055.
43. Koch WM, Brennan JA, Zahurak M, et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88: 1580-1586.
44. Alsner J, Sorensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother Oncol 2001;59:179-185.
45. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birch-all MA, Thomas SJ. Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 2006:31:259-266.
46. Andl T, Kahn T, Pfuhl A, et al. Etiological involvement of oncogenic human papillomavirus in tonsillar squa-mous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998;58:5-13.
47. Wang Y, Okan I, Pokrovskaja K, Wiman KG. Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis. Oncogene 1996;12: 2731-2735.
48. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007;43:415-432.